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ABSTRACT OF THE DISSERTATION 
Effects of Neurotrophic Factors on Osteoblast Growth and 
Differentiation 
 
by 
Colleen M. Moran 
Doctor of Philosophy, Graduate Program in Anatomy 
Loma Linda University, September 2011 
Thomas A. Linkhart, Chairperson 
 
Recent evidence suggests that bone metabolism may be 
influenced by the innervation of skeletal tissues.  Innervation of 
skeletal tissues might directly influence bone volume by the release or 
secretion of osteogenic growth factors in the form of neuropeptides.  
These neuropeptides could act locally on osteoblasts to increase bone 
formation and/or mineralization.  Since calcitonin gene-related peptide 
(CGRP) and Substance P (SP) are the most abundant neuropeptides 
present in sensory nerves in bone, the current studies were intended 
to test the hypothesis that these two neuropeptides may have direct 
effects on osteoblast growth, differentiation, and mineralization.  
Replicate cultures of murine calvarial osteoblasts were grown with and 
without CGRP and/or SP, across a range of physiologic to 
pharmacologic doses.  Cell growth was assessed by changes in cell 
layer protein.  Differentiation was assessed by changes in cellular 
alkaline phosphatase levels, and mineralization was measured by 
xii 
alizarin red staining.  Although we did not observe effects of CGRP or 
SP on cell growth, we did observe effects on differentiation—a 48 hour 
exposure to CGRP induced a dose-dependent increase in alkaline 
phosphatase levels in the calvarial osteoblasts (p<0.001).  Alkaline 
phosphatase activity was also increased in a dose-dependent manner 
following treatment with SP (r =0.979 , p<0.001).  The murine cell 
line MC3T3-E1 was used to determine the effect of CGRP and SP on 
osteoblastic mineralization.  After 7–21 days of continuous treatment 
with CGRP and SP in mineralization media, cells were fixed and 
mineralization was assessed by staining with alizarin red.  The results 
of those studies showed that both CGRP and SP increased the rate and 
the extent of mineralization (p<0.001) and the effects of both 
neuropeptides together were greater than either alone (p<0.001).  
The effects of CGRP, SP, and the combination of peptides on osteoblast 
gene expression, as assessed by RT-PCR, have further revealed that 
exposure to CGRP and/or SP increased the mRNA levels for the Cox 2 
protein, suggesting a possible role for prostaglandins as determinants 
of the osteogenic action(s) of CGRP and SP. 
Together, these findings are consistent with the hypothesis that 
neuropeptides released from neurons in bone may be involved in the 
local regulation of bone volume, by effects on osteoblast growth, 
differentiation, and mineralization. 
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CHAPTER ONE 
INTRODUCTION 
 
Numerous clinical and experimental studies indicate that the 
nervous system influences the regulation of bone growth, remodeling, 
and repair (Chiego and Singh 1981; Singh, Herskovits et al. 1982; 
Aro, Eerola et al. 1985; Hill and Elde 1991; Hukkanen, Konttinen et al. 
1993; Konttinen, Imai et al. 1996; Imai and Matsusue 2002; Togari 
2002; Lerner 2006; Elefteriou 2008; Lerner and Persson 2008; 
Marenzana and Chenu 2008; McGregor, Poulton et al. 2010).  There 
have been many functional studies, which have indicated a role for the 
nervous system in bone volume regulation; for example, during 
embryonic development (Frenkel, Guerra et al. 1990), in fracture 
healing (Aro, Eerola et al. 1985; Asaumi, Nakanishi et al. 2000; 
Koewler, Freeman et al. 2007; Bei, Lin et al. 2009), in peri-implant 
bone remodeling (Buma, Lamerigts et al. 1996; Daimaruya, Nagasaka 
et al. 2001; Gorustovich and Guglielmotti 2001; Abarca, Van 
Steenberghe et al. 2006), in the skeletal response to denervation 
(Garces and Santandreu 1988; Hill and Elde 1991; Duan, Inoue et al. 
1993; Cardozo, Qin et al. 2010; Ding, Arai et al. 2010), and in the 
2 
pathologic process of heterotopic bone formation (van Susante, Buma 
et al. 1996; Ekelund and Erlinge 1997).  
Several lines of evidence suggest that intact innervation is 
essential for proper bone growth and maintenance: bone deprived of 
neural input demonstrates significantly altered growth, repair, and 
remodeling (Smith, Wolff et al. 1958; Hulth and Olerud 1965; Quilis 
and Gonzalez 1974; Frymoyer and Pope 1977; Aro, Kallioniemi et al. 
1981; Chiego and Singh 1981; Aro 1985; Aro, Eerola et al. 1985; Hill 
and Elde 1991; Hukkanen, Konttinen et al. 1993; Nordsletten, Skjeldal 
et al. 1994; Madsen, Wang et al. 1996; Zeng, Jee et al. 1996; Lerner 
2006); brain damage and spinal cord injuries affect bone growth as 
indicated by an increased incidence of excessive callus growth and 
fracture nonunion (Glenn, Miner et al. 1973; Spencer 1987; Garland 
1988; Renfree, Banovac et al. 1994; Banovac, Williams et al. 2004; 
Ivanhoe and Hartman 2004).  Paradoxically, pathological bone growth, 
known as heterotopic ossification, occurs in 20%-40% of people 
following spinal cord injury (Garland 1988; Renfree, Banovac et al. 
1994; Kluger, Kochs et al. 2000; van Kuijk, Geurts et al. 2002; 
Banovac, Williams et al. 2004).  Presumably, these effects are 
dependent on the innervation bone receives from both sensory and 
autonomic nerves, and may also involve the skeletal response to 
different levels of muscle contractile activity and resultant mechanical 
3 
loading (Harrigan and Hamilton 1993; Barros, Muramoto et al. 2007).  
It is also possible that the effects of denervation on the skeleton may 
reflect disruptions in the localized secretion of neuropeptides released 
by those neurons (Konttinen, Imai et al. 1996; Villa, Melzi et al. 2000; 
Schinke, Liese et al. 2004; Offley, Guo et al. 2005; Lerner 2006; 
Lerner and Persson 2008; Naot and Cornish 2008; Han, Zhang et al. 
2010; McGregor, Poulton et al. 2010; Xu, Kauther et al. 2010).  
Neuropeptides found in bone include calcitonin gene-related peptide, 
SP, neuropeptide Y, vasoactive intestinal peptide, nerve growth factor, 
neurotrophin-3, brain-derived neurotrophic factor, and neurokinin A 
(Hill and Elde 1991; Lundy and Linden 2004; Offley, Guo et al. 2005; 
Allison, Baldock et al. 2007; Lerner and Persson 2008; Naot and 
Cornish 2008).  The neuropeptides produced most commonly by 
sensory nerves in bone are calcitonin gene-related peptide (CGRP) and 
Substance P (SP). 
Three key studies strongly support the hypothesis that adverse 
effects of denervation are mediated to a large extent by the reduced 
secretion of neurotrophic factors from nerves innervating bone rather 
than merely by skeletal unloading and decreased mechanical 
stimulation.  Madsen et al. (Madsen, Wang et al. 1996) created 
internally stabilized tibia fractures in rats, then performed sciatic 
neurectomy or sham surgery in the operated leg.  The operated legs of 
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both groups were also immobilized with an external cast so both would 
be subject to loss of mechanical loading.  In nerve intact rats the 
fractured tibias gained 50% of initial strength while fractured tibias of 
the neurectomy group gained only 20% of initial strength, even 
though callus size determined radiographically was larger than in the 
nerve intact group.  Kingery et al. (Offley, Guo et al. 2005) found that 
SP levels in rat tibias fell by 50% after sciatic neurectomy, and that 
bone loss in both denervated and contralateral control tibia was 
increased by 2 week treatment with a SP antagonist LY303870.  Offley 
et al. (Offley, Guo et al. 2005) reported that subcutaneous injection of 
SP antagonist capsaicin induced a 57% loss of unmyelinated peripheral 
sensory nerves without affecting motor nerves.  This resulted in 
reduced bone density in the tibia and femur, with no effects on body 
weight, physical activity pattern, or muscle mass.  Bone loss was 
associated with reduced bone formation rate.  The chemical 
neurectomy by capsaicin produced a pathology similar to that 
observed in familial dysautonomia, an autosomal recessive disease 
characterized by loss of unmyelinated peripheral nerves, low bone 
mass, and increased fracture risk (Maayan, Ofek et al. 1985).  These 
results together with observations that neurotrophic factors such as 
CGRP and SP affect osteoblasts suggest that peripheral nerve secretion 
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of these and other neuropeptides contributes to anabolic stimulation 
and maintenance of bone mass. 
Central nervous system regulation of bone metabolism appears 
to originate in the hypothalamus.  Recent studies are focused on leptin 
and the leptin receptor (Tartaglia 1997; Baldock, Sainsbury et al. 
2002; Lerner and Persson 2008; Driessler and Baldock 2010; Qin, 
Bauman et al. 2010).  The signaling form of the leptin receptor (obRb) 
is expressed in the hypothalamus (Tartaglia 1997; Baldock, Sainsbury 
et al. 2002).  Knockout studies targeting the leptin receptor show that 
mice lacking the gene encoding the leptin receptor demonstrate high 
bone mass phenotype (Ducy, Amling et al. 2000; Baldock, Sainsbury 
et al. 2002).  Furthermore, intra-cerebro-ventricular (icv) infusion of 
leptin normalized bone formation and bone mass in these mice (Ducy, 
Amling et al. 2000; Wolf 2008).  Leptin-dependent inhibitory control of 
bone formation is mediated by the sympathetic nervous system 
(Cirmanova, Bayer et al. 2008; Driessler and Baldock 2010; Qin, 
Bauman et al. 2010).  NPY, like leptin, is abundant in the 
hypothalamus and inhibits bone formation through activation of the 
sympathetic nervous system (Elefteriou 2008).  ICV administration of 
NPY inhibits bone formation in normal mice through release of 
norepinephrine and activation of β2-adrenergic receptors on 
osteoblasts (Allison, Baldock et al. 2007).  In leptin knockout mice, 
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ICV NPY administration reverses the high bone density phenotype of 
these mice, suggesting that NPY acts downstream of leptin in the 
hypothalamus (Cohen 2006).  Neuromedin U (NMU) is another 
hypothalamic peptide that, like leptin and NPY, inhibits bone formation 
(Cirmanova, Bayer et al. 2008). 
Networks of peptidergic nerve fibers are present throughout 
bone and are numerous in highly metabolic sites, e.g., periosteum, 
bone marrow, synovium, and osteochondral junctions of growth plates.  
CGRP- and SP-containing nerves have been found in almost every 
region of bone and surrounding soft tissue of rat limbs and are 
particularly concentrated in highly metabolic regions of bone (Bjurholm 
1991; Hukkanen, Konttinen et al. 1993; Konttinen, Imai et al. 1996; 
Madsen, Wang et al. 1996; Goto, Ishizaki et al. 1999; Broome and 
Miyan 2000; Goto, Straka et al. 2002; Imai and Matsusue 2002; Irie, 
Hara-Irie et al. 2002; Aoki, Ohtori et al. 2003; Vandevska-Radunovic, 
Fristad et al. 2003; Kallakuri, Singh et al. 2004; Ljung, Alfredson et al. 
2004; Mrak, Guidobono et al. 2010).  The current studies were 
intended to assess the in vitro effects of these two neuropeptides – 
CGRP and SP – as potential effectors of bone formation and 
mineralization. 
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Calcitonin Gene Related Peptide 
CGRP, a 37-amino-acid peptide, is synthesized as a result of 
alternative splicing, polyA addition, and differential proteolysis of the 
calcitonin gene mRNA and translation product, respectively.  Calcitonin 
gene-related peptides belong to the calcitonin superfamily of peptides 
including also calcitonin, adrenomedullin, and the two recently 
discovered peptides intermedin and calcitonin receptor-stimulating 
peptide (Lerner 2006).  CGRP was originally discovered in 1982, when 
Amara and colleagues showed that alternative RNA processing of the 
calcitonin gene generated mRNAs encoding a peptide they named 
CGRP (Coleman, Tran et al. 2003).  Calcitonin mRNA is derived from 
exons 1-4 while CGRP mRNA is derived from exons 1-3, 5, and 6 of 
the calcitonin gene.  Proteins produced from these mRNAs are cleaved 
within thyroid or neural cells to produce the mature calcitonin encoded 
by exon 4 or CGRP encoded by exon 5, respectively (Figure 1).  In 
thyroid C cells, more than 98% of the mature mRNA from the 
calcitonin/CGRP gene encodes calcitonin (Coleman, Tran et al. 2003).  
In neurons, 99% of the transcripts are processed into an mRNA 
containing exons 1-3, 5, and 6, and translated into CGRP (Coleman, 
Tran et al. 2003).  Regulation of cell type specific mRNA splicing is 
mediated by selective utilization of the 3' splice acceptor of exon 4 
(active in thyroid cells, inactive in nerve cells) and consequent  
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Figure 1.  Calcitonin gene expression demonstrating alternative 
splicing, polyA addition, and differential proteolysis of the calcitonin 
gene mRNA and translation product, respectively.  Calcitonin mRNA is 
derived from exons 1-4 while CGRP mRNA is derived from exons 1-3, 
5, and 6.  Proteins produced from these mRNAs are cleaved within 
thyroid or neural cells to produce the mature calcitonin encoded by 
exon 4 or CGRP encoded by exon 5, respectively. 
From Lehninger Principles of Biochemistry 3rd ed. 
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alternate use of a poly-adenylation sequence in exon 4 that terminates 
the calcitonin mRNA (Lou and Gagel 1999; Coleman, Tran et al. 2003).  
Cell type specific regulation is mediated by an RNA binding protein 
Calcitonin Splice Regulator (CSR) that in nerve cells binds to 
sequences in exon 4 to inhibit utilization of the 3' exon 4 splice 
acceptor.  In nerve cells this allows formation of a mature mRNA 
encoding CGRP from exon 5, and in thyroid cells the absence of CSR 
binding forces inclusion of exon 4 in the processed mRNA and excludes 
exon 5 due to poly-adenosine and sequence termination in exon-4 
(Lou and Gagel 1999; Coleman, Tran et al. 2003). 
The physiologic roles of CGRP are unclear, although it is 
postulated to regulate several processes in the central and peripheral 
nervous system and skin (Hoff, Catala-Lehnen et al. 2002; Han, Zhang 
et al. 2010).  Although CGRP is a potent vasodilator, emerging roles 
for CGRP suggest that it has effects on immune cells and may be 
involved in the inflammatory response (Lundy and Linden 2004; Han, 
Zhang et al. 2010).  Like calcitonin, CGRP inhibits osteoclast activity in 
vitro (Zaidi, Chambers et al. 1987; Akopian, Demulder et al. 2000; 
Cornish, Callon et al. 2001).  In contrast to calcitonin, which targets 
only osteoclasts in bone, evidence indicates that CGRP also targets 
osteoblasts (Valentijn, Gutow et al. 1997; Villa, Dal Fiume et al. 2003; 
Villa, Mrak et al. 2006; Han, Zhang et al. 2010).  Cultured osteoblasts 
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from multiple species demonstrate a characteristic rise in cyclic AMP 
concentration when exposed to CGRP directly (Michelangeli, Fletcher et 
al. 1989; Valentijn, Gutow et al. 1997; Villa, Mrak et al. 2006).  CGRP 
exposure increases insulin-like growth factor –I (IGF-I) in osteoblasts 
(Michelangeli, Fletcher et al. 1989; Vignery and McCarthy 1996; 
Valentijn, Gutow et al. 1997).  CGRP exposure increases interleukin-6 
expression weakly (Sakagami, Girasole et al. 1993) and decreases 
tumor necrosis factor alpha expression (Millet and Vignery 1997).  In 
addition, CGRP has been shown to control osteoblast production of 
cytokines in vitro (Valentijn, Gutow et al. 1997).  Similar to calcitonin 
itself, CGRP inhibits osteoclast resorption directly in culture (Zaidi, 
Chambers et al. 1987) and decreases serum calcium in vivo (Roos, 
Fischer et al. 1986; Struthers, Brown et al. 1986). 
CGRP is found in both central and peripheral neurons, notably 
including nerve fibers throughout bone (Ballica, Valentijn et al. 1999; 
Jimenez-Andrade, Mantyh et al. 2010; Wang, Guo et al. 2010).  CGRP-
positive nerve fibers are particularly concentrated along the epiphyseal 
trabeculae where they maintain cell-cell interactions with bone cells 
(Vignery and McCarthy 1996; Fan, Bouwense et al. 2010; Wang, Guo 
et al. 2010).  With respect to these observations, it should be noted 
that the presence of CGRP-positive nerve fibers in and/or adjacent to 
epiphyseal trabecular bone is consistent with our hypothesis of 
11 
neuropeptide-dependent effects on bone (i.e., as opposed to effects of 
mechanical loading mediated by neuron-dependent muscular 
contraction).  CGRP-producing nerve fibers increased three-fold in 
number during fracture healing (Hukkanen, Konttinen et al. 1993) and 
increased during osteogenesis in post-arthritic bone (Imai and 
Matsusue 2002).  Interestingly, osteoblasts demonstrate functional 
CGRP receptors (Figures 2 and 3) (Bjurholm, Kreicbergs et al. 1992; 
Togari, Arai et al. 1997; Naot and Cornish 2008). 
CGRP binds to a seven transmembrane-spanning G protein-
coupled receptor and CGRP has been observed to induce a dose-
dependent increase of cyclic AMP formation in chick, rat, and mouse 
calvarial osteoblasts and osteoblastic cell lines (Michelangeli, Fletcher 
et al. 1989; Bjurholm, Kreicbergs et al. 1992).  In fetal rat osteoblasts, 
CGRP increased cell number and stimulated thymidine and 
phenylalanine incorporation (Cornish, Callon et al. 1999).  CGRP has 
also been demonstrated to increase thymidine incorporation in human 
osteoblast-like cells (Villa, Melzi et al. 2000).  Bernard and Shih 
reported that CGRP had an osteogenic stimulating effect by increasing 
the number and size of bone colonies in nucleated rat bone marrow 
cells (Bernard and Shih 1990).  Furthermore, Vignery et al. showed 
that CGRP increased both the accumulation of mRNA encoding IGF-I  
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Amino acid sequence of the human CGRP receptor. Some 
residues are conserved within the calcitonin receptor family. 
From Conner et al., 2007 
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Figure 3.  Model for functional CGRP receptor, including ligand-
binding protein (CRLR), coupling protein (RCP), and chapter one 
protein (RAMP). 
From Conner et al., 2005 
 
 
14 
and the production of IGF-I polypeptide by osteoblasts (Vignery and 
McCarthy 1996). 
In vivo studies have demonstrated that targeted expression of 
CGRP in osteoblasts of transgenic mice increased trabecular bone 
density and bone volume at 6 weeks, 3 months, and 10 months 
(Ballica, Valentijn et al. 1999). In this study, mice were engineered to 
express CGRP in osteoblasts by placing the human CGRP gene under 
the control of the rat osteocalcin promoter.  Trabecular bone density 
and bone volume were increased in mice expressing CGRP, compared 
to their control littermates (Ballica, Valentijn et al. 1999) were 
interpreted as evidence that CGRP may affect coupled bone formation 
(i.e., bone formation in response to bone remodeling coupling factors) 
rather than bone modeling (Ballica, Valentijn et al. 1999). 
As shown in Figure 1, CGRP is produced by alternative splicing of 
mRNA transcribed from the calcitonin gene.  Transgenic mouse studies 
in which the coding sequence for the gene is deleted resulted in loss of 
both calcitonin and CGRP expression.  Mice lacking the entire gene 
have significantly greater trabecular bone volume and a 1.5- to 2-fold 
increase in bone formation (Hoff, Catala-Lehnen et al. 2002); 
however, it is not known if the effect was due to eliminating calcitonin, 
CGRP, or both.  Interestingly, specific deletion of the CGRP coding 
sequence of the calcitonin gene resulted in osteopenia caused by 
15 
decreased bone formation in mice (Schinke, Liese et al. 2004).  
Furthermore, treatment with CGRP and calcitonin inhibited bone 
resorption in ovariectomized rats (Vignery and McCarthy 1996). 
 
Substance P 
Substance P (SP) is an 11-amino-acid peptide richly distributed 
in sensory nerve fibers, often co-localizing with CGRP.  SP is a member 
of the tachykinin family of neuropeptides, also known as neurokinins.  
In mammals, two separate genes designated preprotachykinin I (PPT-
I) and preprotachykinin II (PPT-II) encode the tachykinins . The PPT-I 
gene can express four distinct forms of mRNA, all of which encode 
synthesis of SP (Nawa, Kotani et al. 1984).  The four products of the 
tachykinin peptide hormone family include SP, neurokinin A, 
neuropeptide K, and neuropeptide gamma (Carter, Deibel et al. 1990).  
Since its discovery in 1931, SP has been studied as a therapeutic 
target for conditions as diverse as pain, inflammation, emesis, and 
depression (Prabhu, Malde et al. 2005).  This undecapeptide is widely 
distributed in the central and peripheral nervous systems and is 
thought to participate in regulating neuronal survival and degradation, 
cardiovascular and respiratory function, modulation of autonomic 
reflexes, and neurotransmission of pain (O'Connor, O'Connell et al. 
2004).  SP is secreted by nerves as well as inflammatory cells 
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including macrophages, eosinophils, lymphocytes, and dendritic cells 
and acts by binding to the neurokinin-1 receptor (Figure 4) (O'Connor, 
O'Connell et al. 2004). 
With up to four times as much SP transported to peripheral 
branches of primary sensory neurons compared with the dorsal root 
(Harmar, Armstrong et al. 1984), considerable quantities of 
neuropeptides are therefore stored peripherally for subsequent release 
(Figure 5) (Lundy and Linden 2004).  SP has been shown to regulate 
the vasodilator activity of CGRP (Brain, Williams et al. 1985; Brain, 
MacIntyre et al. 1986; Brain and Grant 2004) suggesting that there 
may be a functional significance to the co-localization of the two 
peptides in neurons. 
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Figure 4.  The neurokinin-1 receptor (NR-1R) is a glycoprotein with 
seven putative -helical transmembrance segments, an extracellular 
amino-terminus, and an intracellular carboxyl tail.  The human NK-1R 
consists of 407 amino acid residues and has a relative molecular mass 
of 46 kDa.  The second and third membrane-spanning domains are 
involved in agonist/antagonist binding, the third cytoplasmic loop is 
responsible for G-protein interaction, while the cytoplasmic carboxyl 
terminal contains many serine and threonine residues which when 
phosphorylated, cause desensitization of the receptor in response to 
repeated application of agonist. 
From O’Connor et al., 2004 
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The mechanisms of action and physiological functions of CGRP 
and SP in tissues receiving innervation from neurons that release 
these peptides are not well understood.  Observed functions of CGRP 
and SP include activation of immune and inflammatory responses, 
blood flow regulation, osteoclast inhibition, activation of second 
messenger systems, IGF-I stimulation, Ca2+ regulation, and NO 
regulation in some cells (Michelangeli, Fletcher et al. 1989; Kawase, 
Howard et al. 1995; Vignery and McCarthy 1996; Ballica, Valentijn et 
al. 1999; Villa, Melzi et al. 2000; Fernandez, Chen et al. 2003; 
Kawase, Okuda et al. 2003; Lundy and Linden 2004).  As in many 
physiological modulators, CGRP and SP likely affect cells in the context 
of many other hormones and growth factors, so effects of these 
peptides observed in any experimental model will depend on cell types 
and physiological conditions (Michelangeli, Fletcher et al. 1989; 
Kawase, Howard et al. 1995; Vignery and McCarthy 1996; Ballica, 
Valentijn et al. 1999; Villa, Melzi et al. 2000; Fernandez, Chen et al. 
2003; Kawase, Okuda et al. 2003; Lundy and Linden 2004). 
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Figure 5.  Factors influencing the release of substance P (SP) from 
sensory nerves.  SP is released from dense core vesicles (LDVCs) 
following (1) cleavage of protease-activated receptor-2 (PAR-2) by 
tryptase, (2) bradykinin binding to B2 receptors, (3) sensitization by 
cytokines induced by LPS, or (4) nitric oxide.  Activation of the 
vanilloid receptor and sensitization of sensory nerves by prostaglan-
dins are not shown. Exocytosed SP binds to the neurokinin-1 receptor 
(NK1-R) expressed on endothelial cells causing vaosodilation and 
edema formation, prominent features of neurogenic inflammation.  SP 
also interacts with immune cells inducing T-lymphocyte proliferation.  
NK-1 receptor expression on macrophages and monocytes is not 
shown. As a result of these interactions, SP is believed to act as an 
important mediator of crosstalk between the nervous and immune 
systems.  SP, Substance P; NK1-R, neurokinin 1 receptor; LDCVs, 
large dense core vesicles (containing neuropeptdies); PAR-2, protease-
activated receptor-2; B2, bradykinin receptor; TLR-4, Toll-like 
receptor-4; LPS, lipopolysaccharide; and LBP, lipopolysaccharide 
binding protein.  From Lundy and Linden, 2004 
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Osteoblast Differentiation 
The central thesis of this proposal is that bone growth and 
metabolism are regulated, in part, by the nervous system, specifically 
by neuropeptides and, more specifically, by CGRP and/or SP.  The 
studies summarized in this report were intended to assess the in vitro 
effects of CGRP and SP on osteoblast growth, differentiation, and 
mineralization; and, because our studies did reveal neuropeptide-
dependent differences in differentiation and mineralization, we 
conducted supplemental studies to determine whether these effects 
reflected changes in the patterns of gene expression.  Previous studies 
in several in vitro model systems have shown that temporal expression 
of osteoblast phenotype-related genes may be used to define the 
growth period, the postproliferative matrix-maturation stage, and the 
mineralization stage (Figure 6).  For example, c-fos and c-myc are 
among the genes expressed during the proliferation period (Kitching, 
Qi et al. 2002).  The matrix maturation period is characterized by peak 
levels of alkaline phosphatase as well as the transcription factors 
osterix and Runx2/Cbfa1 (Lian, Stein et al. 1998; Kitching, Qi et al. 
2002; Arnett 2008).  Runx2/Cbfa1 and osterix are essential for bone 
development as demonstrated by the inhibition of bone tissue 
formation in gene deletion mouse models (Komori 2000; Nakashima, 
Zhou et al. 2002).  Runx2/Cbfa1 enhances transcription of bone 
21 
marker genes including type I collagen and osteocalcin (Gutierrez, 
Javed et al. 2002; Lee, Lim et al. 2006).  Runx/Cbfa1 expression was 
not affected in osteoblast lineage cells of osterix-/- mice, while osterix 
expression was absent in Runx2/Cbfa1-/- mice, suggesting that osterix 
functions downstream of Runx/Cbfa1 in transcriptional regulation of 
osteoblast differentiation (Nakashima, Zhou et al. 2002).  Both genes, 
as well as transcription factor Dlx5, are induced by BMP-2, which 
induces osteoblast differentiation.  Dlx5 was reported to independently 
induce expression of Runx/Cbfa1 and osterix in C2C12 mesenchymal 
cells (Lee, Javed et al. 1999). 
During the mineralization period, mRNA transcripts of osteocalcin 
and bone sialoprotein are increased (Lian, Stein et al. 1998; Kitching, 
Qi et al. 2002).  These non-collagenous bone matrix proteins are 
considered important for bone mineralization.  Both mineralization and 
expression of osteoblast stage-specific genes in MC3T3-E1 osteoblasts 
are affected by hormones, growth factors, and extracellular matrix 
proteins (Lian, Stein et al. 2003; Luppen, Leclerc et al. 2003; 
Jadlowiec, Koch et al. 2004; Pornprasertsuk, Duarte et al. 2004).  To 
determine effects of CGRP and SP on osteoblast differentiation, our 
studies examined the effects of these neuropeptides on mRNA levels of 
selected marker genes. 
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Figure 6.  Temporal expression of cell growth and osteoblast 
phenotype-related genes during 35 days of culture of fetal rat 
calvarium-derived osteoblasts as they synthesize a mineralizing 
matrix.  Peak expression levels of each gene, which were determined 
in total cellular RNA prepared at 3-day intervals, define the growth 
period, the post-proliferative matrix maturation stage, and 
mineralization stage. 
(Lian, Stein et al. 1998) 
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We also assessed the effects of CGRP and SP on COX-2 mRNA, 
which codes for a specific inducible isoform of the enzyme, 
cyclooxygenase.  Cyclooxygenase, also known as prostaglandin 
synthase, is the rate limiting enzyme of the synthetic pathway which 
converts arachidonic acid to prostaglandins and related molecules 
(Chikazu, Li et al. 2002).  Recent studies suggest a possible role for 
COX-2 in bone repair (Zhang, Kuroda et al. 2002; Boursinos, 
Karachalios et al. 2009).  A retrospective study by Giannoudis et al., 
(Giannoudis, Pape et al. 2002) described the association between 
nonunion and the use of non-steroidal anti-inflammatory drugs 
(NSAIDS) after injury.  Sixty-three percent of the patients who 
developed nonunions admitted to taking NSAIDS versus 13% in the 
control group (Dahners and Mullis 2004).  Using a rat spine fusion 
model, Dimar et al., reported that posterior fusion rate dropped from 
45% in the placebo group to 10% in the indomethacin-treated group 
(Dimar, Ante et al. 1996).  Simon et al. showed that fracture healing 
failed in mice treated with selective COX-2 inhibitors (celecoxib and 
rofecoxib) and fracture healing also failed in mice homozygous for a 
null mutation for the COX-2 gene (Simon, Manigrasso et al. 2002).  
Osteoblasts increase expression of COX-2 and increase production of 
PGE2 in response to a wide variety of ligands (Wadleigh and 
Herschman 1999) as well as mechanical stress (Norvell, Ponik et al. 
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2004).  COX-2 is produced in bone-forming cells such as osteoblasts 
and osteocytes (Forwood and Turner 1995) and its expression is highly 
regulated by hormones, growth factors, and cytokines both 
systemically and locally (Jones, Tsigkou et al. 2007).  Recent studies 
have shown that SP and CGRP may influence COX-2 expression and/or 
PG release in cells (Ghilardi, Svensson et al. 2004; Bachar, Rose et al. 
2005).  For example, intrathecal administration of SP in rats increased 
PGE2 release into the spinal fluid and SP NK-1 receptor antagonists 
blocked this effect (Vanegas and Schaible 2001).  Activation of CGRP 
or SP receptors results in prostaglandin release in spinal nerves and 
astrocytes (Malmberg and Yaksh 1992; Hua, Chen et al. 1998);  
Peripheral inflammation was found to increase COX-2 expression in 
neurons adjacent to SP CGRP positive neurons in dorsal horn areas 
that transmit pain signals from inflammation (Yamada, Kamiya et al. 
1999).  Prostaglandins in turn act on nerve terminals of primary 
afferents to further release CGRP and SP in a positive feedback loop 
(Figure 7) (Trang, Sutak et al. 2002) and treatment of cultured dorsal 
root ganglion cells with inflammatory cytokine IL-1 ß increased SP 
release and COX-2 expression (Inoue, Muneyuki et al. 1997; Inoue, 
Yamada et al. 1999).  Interleukin 1- ß induced SP release from 
primary afferent neurons through the cyclooxygenase-2 system 
(Inoue, Muneyuki et al. 1997; Inoue, Yamada et al. 1999).  In this  
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Figure 7.  Model illustrating the reciprocal relationship between 
sensory transmitters and prostaglandins in the dorsal horn.  Activity of 
primary afferents in the dorsal horn releases glutamate, SP, and 
CGRP, which activate specific receptors located on neurons and 
astrocytes and mobilize prostaglandins (PG), which act on presynaptic 
receptors to release more sensory transmitters.  These processes 
constitute a positive feedback loop. 
From Trang et al., 2002 
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study, we measured the effects of CGRP and/or SP on COX-2 mRNA 
expression in osteoblastic cells.  The results of these studies are 
anticipated to advance our general understanding of the 
neuropeptidergic influence on osteoblasts and bone growth, and our 
specific understanding of the potential roles of CGRP and SP in this 
process. 
 
Hypothesis 
Proper regulation of bone growth and metabolism is necessary 
for the skeleton to provide its vital mechanical, protective, and 
metabolic functions.  Histomorphometric studies of bone from the 
human iliac crest have revealed that bone formation is determined 
primarily by changes in osteoblast number and, to a lesser degree, by 
changes in osteoblast biosynthetic activity.  Osteoblasts are the bone-
forming cells, which produce bone matrix and respond to the 
physiological and mechanical demands on the skeleton.  In addition, 
osteoblasts relay signals from osteolytic hormones and cytokines to 
osteoclasts by producing RANKL, which activates osteoclast formation 
and bone resorption.  Osteoblast number and function are regulated 
by a number of endocrine, paracrine, and autocrine factors (Goad and 
Tashjian 1993; Konttinen, Imai et al. 1996; Canalis 2000; Goltzman, 
Karaplis et al. 2000; Sooy, Sabbagh et al. 2005).  Recent studies 
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suggest that osteoblasts may also be regulated by the nervous system 
(Hill and Elde 1991; Hukkanen, Konttinen et al. 1993; Grills and 
Schuijers 1998; Asaumi, Nakanishi et al. 2000; Elefteriou 2008; Wang, 
Zhao et al. 2009; Franquinho, Liz et al. 2010).  The central thesis of 
this proposal is that bone growth and metabolism are regulated, in 
part, by the nervous system and, specifically, by neuropeptides.  
Accordingly, knowledge of these regulatory mechanisms would provide 
new insights to the etiologies of neuropeptide-linked bone volume 
regulation and the possible development of neuropeptides as 
treatment modalities for disorders of bone metabolism.  The goal of 
the studies summarized in this proposal was to determine the role of 
the nervous system in the regulation of osteoblast function and bone 
volume regulation.  The specific aims of this proposal were intended to 
assess the following hypotheses. 
 Hypothesis 1.  CGRP and/or SP have direct, osteogenic effects on 
the number of osteoblast-line cells in bone and/or the extent of 
osteoblastic differentiation. 
 Hypothesis 2.  CGRP and/or SP have direct effects on osteoblast-
line cells to increase mineralization. 
 Hypothesis 3.  The osteogenic effects of CGRP and/or SP are 
dependent on changes in the expression of stage-specific osteoblast 
genes. 
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Specific Aims 
Specific Aim#1.  Determine whether the exogenous application 
of the neuropeptides CGRP and SP increases osteoblast growth and 
differentiation, as assessed by changes in cell layer protein and 
skeletal alkaline phosphatase activity, respectively.  (Skeletal alkaline 
phosphatase is an ecto-enzyme, and is regarded as a marker of 
mature osteoblasts (Manolagas, Burton et al. 1981; Bianco, Riminucci 
et al. 1993; Lian, Stein et al. 1998).  Neonatal mouse calvaria cells 
and the MC3T3-E1 cell line were used for Aim #1. 
Specific Aim #2.  Determine whether the exogenous application 
of the neuropeptides CGRP and SP increases osteoblast mineralization, 
when mineralization as assessed by comparing calcium deposition 
after 7–14 days of growth with and without neuropeptides. 
Mineralization is determined by the quantitation of alizarin red staining 
(Hessle, Johnson et al. 2002; Dallas, Veno et al. 2009).  The mouse 
osteoblast cell line MC3T3-E1 was used for Aim #2. 
Specific Aim #3.  Determine whether the osteogenic effects of 
exogenous neurotrophic factors (i.e., CGRP and SP) are associated 
with or determined by changes in the expression of stage-specific 
osteoblast genes.  The most significant genes that are transcribed and 
translated in osteoblasts are those dealing with the synthesis of an 
extracellular matrix, i.e., collagenous and noncollagen matrix proteins 
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(Canalis 2000), and transcription factors that regulate osteoblast 
differentiation.  Relative levels of mRNA for a variety of osteoblast-
specific proteins and regulatory enzymes were quantified by real-time 
polymerase chain reaction (RT-PCR).  The MC3T3-E1 cell line was used 
for these studies. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Materials 
Dulbecco’s Modified Eagle Medium (DMEM) was purchased from 
Mediatech (Herndon, VA).  -Minimum Essential Medium was from 
Gibco-Invitrogen (Grand Island, NY).  Bovine calf serum (CS) and Fetal 
bovine serum (FBS) were obtained from Atlanta Biologicals (Norcross, 
GA).  Tissue culture ware was obtained from Becton Dickenson 
(Franklin Lakes, NJ) and Corning Life Sciences (Fisher Scientific, 
Pittsburg, PA).  All other chemicals were purchased from Sigma (St. 
Louis, MO) or Fisher Scientific (Chino, CA).  RNA purification kits were 
purchased from Gentra Systems (ISIS, Wicklow, Ireland), First-Strand 
cDNA Synthesis kits for RT-PCR were from Invitrogen (Carlsbad, CA), 
and Quantitech SYBER Green PCR kits were from Qiagen (Valencia, 
CA). 
 
Cell Culture 
Calvarial osteoblasts were isolated by collagenase digestion from 
2–3 day old Swiss-Webster mice obtained from Harlan, using standard 
techniques (Michelangeli, Fletcher et al. 1989; Bjurholm, Kreicbergs et 
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al. 1992; Arnett 2003).  Osteoblasts were collected and grown to 80% 
confluence in DMEM containing 10% CS at 37°C with 5% CO2.  For 
measurements of mineralization, MC3T3-E1 cells obtained from Dr. 
Baruch Frenkel at the University of Southern California (Smith, McCabe 
et al. 2006) were cultured in -MEM containing 10% FBS at 37°C with 
5% CO2.  The NIH 3T3 mouse embryo fibroblast cell line was from 
ATCC. 
 
 
Neuron Osteoblast Co-Cultures 
Neurons were isolated from fetal rat neocortex and included 
65% cortical neurons and 35% glial cells.  Blocks of tissue were placed 
on glass cover slips and cultured in 35 mm culture dishes.  Osteoblasts 
were divided into three experimental conditions: (1) osteoblasts only, 
in which two cover slips were placed into a small culture dish; (2) 
osteoblasts plus neurons, in which a single cover slip containing 
osteoblasts was placed into a culture dish together with a single cover 
slip of neurons placed at a distance to prevent physical contact with 
osteoblasts, and (3) osteoblasts plus fibroblasts, in which a cover slip 
containing osteoblasts was placed into a petri dish containing a cover 
slip of fibroblasts.  Culture dishes contained 2 ml of serum-free 
F12/Delbecco’s Modified Essential Medium (Sigma, St. Louis, MO).  
Serum-free media was chosen to eliminate the possibility of trophic 
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factors in fetal calf serum that could affect the growth of the 
osteoblasts.  A total of five repeat experiments were performed, in 
which each experiment contained five or more petri dishes for each 
experimental condition. All cultures were maintained at 37°C with 5% 
CO2 and visually inspected each day for seven days at which time the 
osteoblasts were stained for alkaline phosphatase activity as described 
(Lundy et al. 1991). 
Following staining, the cover slips containing osteoblasts were 
attached to glass slides with mounting medium and analyzed on a 
Nikon Optiphot microscope with Normarski Optics.  In practice, a 
10x10 net eyepiece graticule was used to calculate cell area and 
density on each cover slip.  Each adjacent non-overlapping area, 
constituting one vertical sweep through the center of the cover slip, 
was photographed and analyzed.  Alkaline phosphatase positive areas 
were photographed with a digital microscope camera (Aphogee Inc., 
Temecula, CA), and analyzed using a computer image software 
program (Scion Image).  All statistical analyses were made using 
ANOVA (Microsoft Excel, Redmond, WA) with Bonferroni post-hoc 
comparisons.  A probability of less than 0.05 was considered 
significant. 
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Measurement of ALP Activity  
Swiss Webster calvarial osteoblasts were plated in 24-well plates 
in DMEM with 10% CS at 30,000–40,000 cells/ml (Lundy et al. 1991; 
Farley et al. 2005).  Twelve hours later, the medium was replaced with 
serum-free DMEM and neuropeptides or equivalent amounts of dilution 
buffer were added to replicate wells (n=3).  After 48 hours of 
continuous exposure, replicate cell cultures were rinsed with PBS, then 
scraped and homogenized by agitation with a disposable transfer 
pipette and extracted in 0.01% Triton X-100 (vol/vol).  Alkaline 
phosphatase activity was measured in these extracts by the rate of 
hydrolysis of ρ-nitrophenylphosphate (10 mM), in 200 mM 
carbonate/tris buffer at pH 10.3, in the presence of 1 mM MgCl2.  
Using the method of Lundy (Lundy et al. 1991) and Farley (Farley et 
al. 2002), ρ-nitrophenolate production was measured as the time-
dependent increase in optical density at 410 nm, using an automated 
microtiter-plate spectrophotometer (SLT LabInstruments Easy Reader 
Ear 400AT).  Alkaline phosphatase specific activity was calculated as 
U/mg protein, where 1 U ALP activity = 1 mol product (ρ-nitro-
phenolate) formed per minute at 22°C.  The dye binding method of 
Bradford (Bradford 1976; Schleicher and Wieland 1978; Compton and 
Jones 1985; Noble and Bailey 2009) was used to determine total cell 
layer protein concentration in the extracts, using BSA standards and 
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blanks also prepared in 0.01% triton X-100.  Alkaline phosphatase 
levels were normalized to protein levels in order to calculate alkaline 
phosphatase specific activity. 
 
Alkaline Phosphatase Assay Protocol 
1. Remove media and rinse cells 3 times with PBS. 
2. Add 0.25 ml 0.01% Triton X-100 to each well (24 well plate) to 
extract cells. 
3. Scrape the cell layer, using cell scraper or plastic pipette tip, and 
mix the solution by repeat pipetting. 
4. Transfer aliquots of cell layer extract of each sample (0.05 ml) into 
wells of 96-well plate and add 0.250 ml of the ALP substrate 
solution to every well to start the reaction. 
5. Take an initial OD reading (410 nm with a reference wavelength of 
490 nm) as soon as the substrate is added and a final reading after 
incubating at room temperature when the solutions are visibly 
yellow. 
6. Calculate ALP activity: 1 milliunit equals 1 nm of product produced 
per minute (milliunit/ml of extract = Change in OD x 410 / OD 
standard x 1/time in minutes) 
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Mineralization 
MC3T3-E1 cells were plated in 6-well plates at 30,000–40,000 
cells/ml, in a volume of 2.0 ml/well.  When the cells were 80% 
confluent, the culture medium was supplemented with 50 g/ml 
ascorbic acid and 10 mM ß-glycerolphosphate to support 
mineralization with and without addition of neuropeptides; 3 replicate 
wells for each dose of neuropeptide and 3 replicate control wells 
containing an equivalent amount of the dilution buffer were compared.  
Media was replaced and fresh peptides were added every other day.  
After 7–14 days, cells were rinsed 5 times with PBS and fixed for one 
hour at 4°C with 10% formalin in PBS.  Alizarin red solution (40mM, 
pH 4.2) was applied to the fixed cells for 10 minutes at room 
temperature.  Alizarin red staining was quantified by extracting the 
calcium-bound dye with cetylpyridinium chloride (a 10% w/v solution 
in water, 1.0 mL per 6-place well) and reading the absorbance at 570 
nm (Hessle, Johnson et al. 2002). 
 
Alizarin Red/Cetylpyridinium Chloride (CPC) Protocol 
1. Remove media and wash cells 5 times with PBS. 
2. Fix with 10% Formalin in PBS (Fischer Scientific) for 60 minutes at 
4°C.  (1 ml /well for 6-well plates) 
3. Wash culture gently 5 times with PBS and Nanopure water. 
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4. Stain with 40 mM Alizarin Red (p.H. 4.2) at room temperature for 
15 minutes.  (1 ml/well for 6-well plates) 
5. Wash gently 5 times with Nanopure water, rinse with PBS for 15 
minutes to reduce nonspecific staining. 
6. Photograph using light box. 
7. Destain with 10% (w/v) CPC in 10 mM sodium phosphate buffer 
(p.H. 7.0) for 60 minutes at room temperature with gentle rotation.  
(1 ml/well in 6-well plates) 
8. Dilute aliquots 10-fold in 10% CPC solution in 96-well plate in 
triplicate. 
9. Measure absorbance at 562 nm for quantification. 
 
mRNA Measurements by RT-PCR 
Replicate 100 mm-diameter dishes of Swiss-Webster calvarial 
osteoblasts and/or MC3T3-E1 cells were exposed to doses of effectors 
(including zero effector controls).  Following treatment (i.e., 24–96 
hours of continuous exposure) with neuropeptides, total cellular RNA 
was extracted from individual dishes of control and experimental cells 
using a Versagene RNA purification kit.  RNA concentration was 
determined at A260 using Nanodrop spectrophotometer (NanoDrop 
Technologies Inc., Wilmington, DE).  cDNA templates for RT-PCR were 
synthesized from 1 µg of total RNA by reverse transcription reaction 
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using a SuperScript III First Strand cDNA Synthesis kit (Invitrogen, 
Carlsbad, CA) and a PTC-150 MiniCycler (MJ Research Inc., Waltham, 
MA).  Relative levels of mRNA were quantified using real-time 
polymerase chain reaction with a Quantitech SYBER Green PCR kit 
(Qiagen, Valencia, CA) and DNA Engine Opticon System (MJ Research/ 
BioRad, Hercules, CA).  For each 20 µl reaction, 2 µl of Superscript III 
RT reaction product was used as template with 10 µM primer pairs 
described in Table 1.  Fluorescence of SYBER Green dsDNA binding dye 
was measured by the Opticon detector and cycle threshold data were 
analyzed using Opticon Monitor software. 
Briefly, the PCR parameters were denatured at 95°C for 10 
minutes; followed by 35 cycles of 95°C for 1 minute, 56.6°C for 30 
seconds, 72°C for 1 minute.  Melting curve-analysis was performed by 
the Opticon System to analyze product homogeneity; and gel 
electrophoresis was performed for further confirmation.  Osteoblast 
stage-specific primers for mouse type I1 collagen, alkaline 
phosphatase, bone sialoprotein, osteocalcin, Runx2/Cbfa1, COX-2, and 
osterix (Table 1) were used to determine the effect of neuropeptides 
on mRNA levels of osteoblast stage-specific proteins.  Cyclophilin was 
used as a housekeeping gene for normalizing each sample.  The 
characteristics of each of the PCR primer pairs are summarized in the 
following table (Table 1). 
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Table 1.  RT-PCR Primer List.  Primer names indicate 5' base pair 
position in sequence of Genbank Accession number, and forward (F) or 
reverse (R). 
 
 
Protein Primer Name 
Accession 
Number 
% 
GC 
Tm 
ºC 
# 
bp sequence 
Osterix mOSX 1152F NM_130458 55.0 57.8 20 5'-cac ttg cct gct ctg ttc ca-3' 
Osterix mOSX 1350R NM_130458 50.0 55.6 20 5'-cgg ctg att ggc ttc ttc tt-3' 
Cbfa1 mCbfa1 41F NM_009820 55.0 57.9 20 5'-gcg gtg caa act ttc tcc ag-3' 
Cbfa1 mCbfa1 144F NM_009820 42.9 55.0 21 5'-ggc tgc aag cag tat tta caa-3' 
Cbfa1 mCbfa1 273R NM_009820 55.0 58.3 20 5'-ggt gct cgg atc cca aaa ga-3' 
Cbfa1 mCbfa1 523R NM_009820 63.2 59.9 19 5'-cca tgg tgc ggt tgt cgt g-3' 
Osteocalcin mOC 362F NM_031368* 55.0 55.3 20 5'-gct acc ttg gag ctt cag tc-3'  
Osteocalcin mOC 485R NM_031368 55.0 58.8 20 5'-atg cgt ctg tag gcg gtc tt-3' 
Collagen (I) mcol1a1f1432 BC003198 55.0 58.3 20 5'-gac ctt cct gcg cct aat gt-3' 
Collagen (I) mcol1a11602R BC003198 50.0 55.5 20 5'-ctg tag gtg aag cga ctg tt-3' 
Bone 
Sialoprotein mBSPf733 NM_008318 55.0 58.2 20 5'-agg tgc aga agg aac cac ag-3' 
Bone 
Sialoprotein mBSP989R NM_008318 50.0 54.8 20 5'-cgt cct cat aag ctc ggt aa-3' 
Alkaline 
Phosphatase mALP 1984F X13409 60.0 60.5 20 5'-cca gac cct gca acc tcc at-3' 
Alkaline 
Phosphatase mALP 2253R X13409 55.0 58.8 20 5'-ggt tgg cga gtc tct gca at-3' 
Alkaline 
Phosphatase mALP 2272R X13409 55.0 55.9 20 5'-gag agc cac ttc agt gaa gg-3' 
Cyclophilin rmcyclophilin 
315 F BC059141 55.0 57.9 20 5' gca tac agg tcc tgg cat ct 3' 
Cyclophilin rmcyclophilin 
505 R BC059141 50.0 56.6 20 5' tct tgc tgg tct tgc cat tc 3' 
Cyclophilin rmcyclophilin 
596 R BC059141 55.0 55.1 20 5' gct ctc ctg agc tac aga ag 3' 
 
Subsequent to finishing these experiments, NM_031368 was identified 
as mouse osteocalcin-related gene, and not actual osteocalcin 
(Petrucci et al. 2006). 
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Total RNA was isolated at 0, 1, and 3 days from control cells and 
cells treated with CGRP plus SP.  Relative mRNA expression levels of 
each sample were determined by quantitative RT-PCR with the 
comparative Ct method.  The Ct (cycle threshold) value represents the 
PCR amplification cycle at which the fluorescent signal exceeds a 
background threshold level (Figure 24).  After determining Ct for each 
gene, relative levels of each osteoblast marker gene were normalized 
to mRNA levels of the housekeeping gene cyclophilin.  Each sample 
was analyzed for each osteoblast gene in duplicate in at least three 
experiments, and cyclophilin was assessed in the same assay each 
time.  A Ct value was obtained for each osteoblast gene mRNA by 
subtracting the Ct value of cyclophilin mRNA from the Ct value of the 
mRNA for each sample.  To compare relative mRNA levels between 
treated and untreated cells at each time point, Ct was calculated as 
Control Ct – TreatedCt.  The ratio of Treated/Control mRNA levels 
was calculated as 2(∆∆Ct).  Ct value represents threshold cycle for PCR 
amplification cycle between cycle and reference. 
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Versagene Total RNA Purification Protocol 
1. Remove media and rinse cells 3 times with PBS. 
2. Thoroughly homogenize sample in appropriate volume calculated 
using cell number (3 x 104 – 1 x 106 cells use 200 l of Lysis 
solution). 
3. Pipette 400l of lysate onto Purification Column and centrifuge at 
13,000–16,000 x g for 1 minute. 
4. Apply lysate onto column in 400 l aliquots and centrifuge at 
maximum speed after each addition of 400 l lysate. 
5. Transfer basket containing Purification Column to a new tube. 
6. Add 400 l Wash 1 to Purification Column and centrifuge at 13,000–
16,000 x g for 1 minute. 
7. Transfer basket containing Purification Column to new tube. 
8. Apply 50 l DNase solution to the column and incubate at room 
temperature for 15 minutes. 
9. Add 200 l DNase Wash Solution to the column and centrifuge at 
13,000–16,000 x g for 1 minute. 
10. Add 200 l DNase Wash Solution to the column and centrifuge at 
13,000–16,000 x g for 2 minutes. 
11. Transfer column to new tube. 
12. Add 200 l Wash 2 Solution to the Purification Column and 
centrifuge at 13,000–16,000 x g for 1 minute. 
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13. Add an additional 200 l Wash 2 Solution to the purification Column 
and centrifuge at 13,000–16,000 x g for 2 minutes. 
14. Transfer basket containing Purification Column to a new tube. 
15. Add 50–100 l Elution Solution to the Purification Column and 
centrifuge at 13,000–16,000 x g for 1 minute. 
16. Discard basket, place tube containing purified RNA on ice and store 
at -80oC. 
17. Make A260 and A280 readings with Nanodrop. 
 
First-Strand cDNA Synthesis Using SuperScriptTM III 
for RT-PCR 
1. Add the following components to a nuclease-free tube: 
1 l of oligo (dT)20 (2 nM) 
1 g total RNA (in up to 11 μl) 
1 l 10mM dNTP Mix, pH7.0 (10 mM each dATP, dGTP, dCTP) 
RNAse, DNAse free H2O to final volume of 11 μl 
2. Heat mixture to 65°C for 5 minutes and incubate on ice for at least 
1 minute. 
3. Collect the contents of the tube by brief centrifugation and add: 
4 l 5X First-Strand Buffer  
1 l 0.1 M DDT 
1 l RNase OUTTM Recombinant RNase Inhibitor  
1 l SuperScriptTM III RT (200 units/l) 
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4. Mix by pipetting gently up and down. 
5. Incubate at 50°C for 30–60 minutes. 
6. Inactivate the reaction by heating at 70°C for 15 minutes. 
7. To remove RNA complementary to the cDNA, add 1 l (2 units) E. 
coli. RNase H and incubate at 37°C for 20 minutes. 
 
Statistical Analysis 
Data are presented as averages of replicates (mean +/- 
standard error).  Statistical analyses were performed with Systat 
software (Point Richmond, CA).  Group comparisons were made by 
one- and two-way analysis of variance with Tukey’s post hoc 
comparison.  Correlations were assessed by linear regression.  In order 
to minimize the effects of interassay variation, statistical methods 
were limited to intraassay group comparisons (i.e., except where 
specified as otherwise).  All reported observations were confirmed in a 
minimum of three experiments.  Minimal statistical significance was 
defined as p< 0.05. 
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CHAPTER THREE 
RESULTS 
 
Preliminary data demonstrated that rat calvarial osteoblasts 
cultured in media shared with primary cortical neurons demonstrated 
more intense staining for alkaline phosphatase (Figure 8).  In this 
study, neurons were isolated from fetal rat neocortex and included 
65% cortical neurons and 35% glial cells.  Osteoblasts were divided 
into three experimental conditions: (1) osteoblasts only, in which two 
cover slips containing osteoblasts were placed into a small petri dish; 
(2) osteoblasts plus neurons, in which a single cover slip containing 
osteoblasts was placed into a petri dish together with a single cover 
slip of neurons placed at a distance to prevent physical contact with 
osteoblasts, and (3) osteoblasts plus fibroblasts, in which a cover slip 
containing osteoblasts was placed into a petri dish containing a cover 
slip of fibroblasts.  Osteoblasts cultured in the presence of neurons 
demonstrated significant increases in cell number and cell area 
compared to osteoblasts cultured without neurons (Figures 8–10).  
From this, we inferred that the neurons can produce growth and/or 
differentiation factors which can be active on osteoblasts. 
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Figure 8.  Photomicrograph of alkaline phosphatase staining (A) 
control rat osteoblasts, (B and C) osteoblast grown in the presence of 
fibroblasts, and (D) osteoblasts grown in the presence of primary rat 
cortical neurons. 
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Figure 9.  Number of osteoblasts after 7 days in culture as described in 
Methods.  Significantly greater numbers of osteoblasts were obsevered 
when co-cultured with primary cortical neurons than in the other two 
conditions (p<0.0001). n=5 
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Figure 10.  Measurement of the area of osteoblast cell bodies in culture 
for 7 days.  Osteoblasts co-cultured with primary cortical neurons had 
significantly larger cell bodies compared to two other groups 
(p<0.001). n=5 
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Effects of Neuropeptides on Cell Layer Protein and 
AlkalinePhosphatase Levels 
Initially, in vitro experiments with osteoblast cell cultures were 
done with mouse calvarial osteoblasts.  A series of experiments 
established that treatment of calvarial osteoblasts with CGRP 
(0.01g/mL, 0.1g/mL, 1.0g/mL, 10g/mL) induced a significant dose 
dependent increase in alkaline phosphatase specific activity when 
compared with controls (Figures 11-13).  Pearson correlation indicates 
r=0.950 (Figure 13).  Total cell protein was not significantly affected, 
suggesting that the neuropeptides did not affect osteoblast 
proliferation.  When cells were treated with SP (tested at 0.01g/mL, 
0.1g/mL, 1.0g/mL, and 10g/mL), analysis by ANOVA did not reveal 
similar group-specific differences in alkaline phosphatase specific 
activity.  However, these experiments consistently showed a significant 
correlation between SP dose and ALP specific activity when the data 
were analyzed by Pearson correlation (Figures 14-17).  Interaction 
studies showed that osteoblasts treated with both CGRP and SP had 
significantly higher alkaline phosphatase specific activity compared to 
controls and these levels were higher than in cultures treated with 
CGRP or SP alone (Figures 16-21).  
Effects of the neurotrophin nerve growth factor (NGF) were also 
examined using various dilutions (0.01g/mL, 0.1g/mL, 1.0g/mL, 
48 
and 10g/mL).  Nerve growth factor did not affect protein or ALP levels 
after 48 hours of treatment. 
The same series of experiments was performed using MC3T3-E1 
osteoblastic cells; however, there was no effect on protein or ALP 
levels following 48 hours of treatment with any of the neuropeptides 
alone or in combination. 
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Figure 11.  Swiss-Webster mouse calvarial osteoblasts treated with 
CGRP for 48 hours.  Alkaline phosphatase (ALP) specific activity was 
measured as described in the Methods.  Significant increase in ALP 
specific activity was observed at 0.1, 1.0, and 10 µg/ml CGRP 
(p<0.001). n=3 
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Figure 12.  Swiss-Webster mouse calvarial osteoblasts treated with 
CGRP for 48 hours.  Alkaline phosphatase (ALP) specific activity was 
measured as described in the Methods.  Significant increase in ALP 
specific activity was observed at 0.1, 1.0, and 10 µg/ml CGRP 
(p<0.001). 
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Figure 13.  Dose-dependent increase in alkaline phosphatase specific 
activity (mU/mg) in Swiss-Webster mouse calvarial osteoblasts after 
48 hours of treatment with CGRP concentration 0.01, 0.1, 1.0, 
10g/mL as described in Methods.  Alkaline phosphatase specific 
activity was measured as described in Methods.  Data shown as 
samples of replicates (n=4).  Pearson correlation indicates r=0.950, 
p<0.001. 
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Figure 14.  Swiss-Webster mouse calvarial osteoblasts treated with SP 
for 48 hours.  Alkaline phosphatase (ALP) specific activity was 
measured as described in the Methods.  ALP specific activity was 
correlated with dose of SP at 0.1, 1.0, and 10 µg/ml SP (r=0.979; 
p<0.001). 
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Figure 15.  Swiss-Webster mouse calvarial osteoblasts treated with SP 
for 48 hours.  Alkaline phosphatase (ALP) specific activity was 
measured as described in the Methods.  ALP specific activity was 
correlated with dose of SP at 0.1, 1.0, and 10 µg/ml SP (r=0.817; 
p<0.01). 
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Figure 16.  Swiss-Webster mouse calvarial osteoblasts treated with SP 
for 48 hours.  Alkaline phosphatase (ALP) specific activity was 
measured as described in the Methods.  ALP specific activity was 
correlated with dose of SP at 0.1, 1.0, and 10 µg/ml SP (r=0.910; 
p<0.01). * r= 0.910 
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Figure 17.  Dose-dependent increase in alkaline phosphatase specific 
activity (mU/mg) in Swiss-Webster mouse calvarial osteoblasts after 
48 hours of treatment with SP concentration 0.01, 0.1, 1.0, 10g/mL 
as described in Methods.  Alkaline phosphatase specific activity was 
measured as described in Methods.  Data shown as samples of 
replicates (n=4).  Pearson correlation indicates r=0.971, p<0.01. 
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Figure 18.  Swiss-Webster mouse calvarial osteoblasts treated with 
CGRP and SP for 48 hours.  Alkaline phosphatase (ALP) specific activity 
was measured as described in the Methods.  Significant increase in ALP 
specific activity was observed at combinations of 1 µg/ml CGRP and SP 
and 10 µg/ml CGRP and SP (p<0.001). 
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Figure 19.  Swiss-Webster mouse calvarial osteoblasts treated with 
CGRP and SP for 48 hours.  Alkaline phosphatase (ALP) specific activity 
was measured as described in the Methods.  Significant increase in ALP 
specific activity was observed at combinations of 1 µg/ml CGRP and SP 
and 10 µg/ml CGRP and SP (p<0.001).
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Figure 20.  Swiss Webster mouse calvarial osteoblasts treated with SP, 
CGRP, and SP + CGRP in combination.  Alkaline phosphatase (ALP) 
specific activity was measured as described in the Methods.  
Significant increase in ALP specific activity was observed at 1 µg/ml 
CGRP and 1 µg/ml CGRP + 1 µg/ml SP (p<0.001). 
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Figure 21.  Dose-dependent increase in alkaline phosphatase specific 
activity (mU/mg) in Swiss-Webster mouse calvarial osteoblasts after 
48 hours of treatment with CGRP + SP concentration 1g/mL CGRP + 
1g/mL SP, 10g/mL CGRP +10g/mL SP as described in Methods.  
Alkaline phosphatase specific activity was measured as described in 
Methods.  Data shown as samples of replicates (n=4).  Pearson 
correlation indicates r=0.987, p<0.001. 
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Effects of Neuropeptides on Osteoblastic 
Mineralization 
A series of studies revealed that both CGRP and SP reproducibly 
increased the rate and the extent of mineralization in MC3T3-E1 
osteoblastic cells as measured by alizarin red staining.  Alizarin red 
staining correlates with Von Kossa staining, infrared spectroscopy, and 
calcium content as an indicator of bone mineral accumulation in 
cultured MC3T3-E1 cells and other in vitro models (Luppen, Leclerc et 
al. 2003; Jadlowiec, Koch et al. 2004; Naito, Kaji et al. 2005).  We 
found that CGRP produced an effect on mineralization, as evidenced by 
greater area and intensity of staining after 7–14 days of treatment 
(Figures 22-24).  SP produced a similar effect on mineralization, as 
evidenced by greater area and intensity of staining (Figure 25).  After 
5–6 days of growth, the treated cells appeared to form groups of cells 
on top of each other, which is typical of these cells just prior to 
mineralization, and there was robust mineralization by 8–10 days.  
Untreated cells underwent the same morphological changes after 10–
12 days and mineralized by 14–16 days.  Extraction of the alizarin red 
stained cultures with CPC allowed quantitative comparisons and those 
extraction studies showed significant increases in alizarin red 
absorbance following treatment with CGRP, SP, and combination of the 
two peptides (Table 2). 
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Figure 22.  Mineralization of MC3T3-E1 osteoblastic cells after 7 days 
of growth with and without CGRP.  On day 7, cells were stained with 
alizarin red for calcium deposition.  Alizarin red staining demonstrates 
increased calcium deposition with CGRP treatment compared to 
controls. 
 
 Control                     0.1 g/ml CGRP  
  
62 
 
 
Figure 23.  Mineralization of MC3T3-E1 osteoblastic cells after 7 days 
of growth with and without CGRP.  On day 7, cells were stained with 
alizarin red for calcium deposition.  Alizarin red staining demonstrates 
increased calcium deposition with CGRP treatment compared to 
controls. 
     
    Control                     1.0 g/ml CGRP  
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Figure 24.  Histochemical demonstration of Alizarin Red stain in 
MC3T3-E1 cells after 7 days growth with and without CGRP.  
Photomicrographs show mineral deposition in cells treated with CGRP 
compared to control; magnification, 4x. 
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64 
 
 
 
 
 
    Control      1.0 g/ml SP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25.  Mineralization of MC3T3-E1 osteoblastic cells after 14 days 
of growth with and without SP.  On day 14, cells were stained with 
alizarin red for calcium deposition.  Alizarin red staining demonstrates 
increased calcium deposition with SP treatment compared to controls. 
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                                    Control       1.0 g/ml SP & 1.0 g/ml CGRP 
 
                    
 
 
Figure 26.  Mineralization of MC3T3-E1 osteoblastic cells after 7 days 
of growth with and without SP & CGRP in combination.  On day 7, cells 
were stained with alizarin red for calcium deposition.  Alizarin red 
staining demonstrates increased calcium deposition with SP & CGRP 
combined compared to controls. 
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Table 2.  Alizarin red staining of MC3T3-E1 osteoblastic cells was 
quantified by extracting the calcium-bound dye with cetylpyridinium 
chloride (CPC) and reading the absorbance at 562 nm as described in 
Methods.  Extraction studies showed significant increases in alizarin 
red absorbance following treatment with 1.0 g/mLCGRP, 1.0 g/mL 
SP, and combination of 1.0 g/mL of the two peptides (p<0.001). 
 
 
CPC Measurements A562 
Control CGRP 
179.8 378.0 
209.6 356.9 
198.7 320.2 
  
Control SP 
183.2 225.1 
170.0 253.7 
171.5 272.3 
  
Control CGRP + SP 
177.3 375.4 
206.9 403.3 
187.4 396.9 
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mRNA Measurements 
Total RNA was isolated at 0, 1, and 3 days from control cells and 
cells treated with CGRP plus SP.  Relative mRNA expression levels of 
each sample were determined by quantitative RT-PCR with the 
comparative Ct (cycle threshold) method.  The Ct value represents the 
PCR amplification cycle at which the fluorescent signal exceeds a 
background threshold level.  After determining Ct for each gene, 
relative levels of each osteoblast marker gene were normalized to 
mRNA levels of the housekeeping gene cyclophilin.  Each sample was 
analyzed for each osteoblast gene in duplicate in at least three 
experiments, and cyclophilin was assessed in the same assay each 
time.  A Ct value was obtained for each osteoblast gene mRNA by 
subtracting the Ct value of cyclophilin mRNA from the Ct value of the 
mRNA for each sample.  To compare relative mRNA levels between 
treated and untreated cells at each time point, Ct was calculated as 
Control Ct – TreatedCt.  The ratio of Treated/Control mRNA levels 
was calculated as 2(∆∆Ct). 
Relative mRNA expression levels of alkaline phosphatase, bone 
sialoprotein, osterix, osteoclacin, cbfa1, and collagen did not 
demonstrate measurable differences at the time points tested (1 and 4 
days of treatment with neuropeptides) using RT-PCR.  Relative mRNA 
expression levels of COX-2 were significantly increased in MC3T3-E1 
68 
osteoblastic cells treated with neuropeptides compared to control 
(Table 3-5).  This effect was significant after 4 days of continuous 
treatment with CGRP and/or SP (p<0.001). 
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Table 3.  Original: RT-PCR data after 4 days culture with and without 
neuropeptides showing cycle threshold C(T) value, which represents the 
PCR amplification cycle at which the fluorescent signal exceeds a 
background threshold level.  A Ct value was obtained for each 
osteoblast gene mRNA by subtracting the Ct value of cyclophilin mRNA 
from the Ct value of the mRNA for each sample.  To compare relative 
mRNA levels between treated and untreated cells at each time point, 
Ct was calculated as Control Ct – TreatedCt.  The ratio of 
Treated/Control mRNA levels was calculated as 2(∆∆Ct).  Ct value 
represents threshold cycle for PCR amplification cycle between cycle 
and reference.  ∆∆Ct represents the difference between ∆Ct(treated sample) 
and ∆Ct(untreated sample) for the same gene. 
 
 
  C(T)  ΔCt  ΔΔCt  2(ΔΔCt) 
CONTROL COX‐2  23.25 9.33      
CGRP COX‐2  22.03 9.94 ‐0.61  0.66
SP COX‐2  23.87 8.53 0.80  1.74
BOTH COX‐2  21.64 7.78 1.55  2.93
RT NEG  NONE          
              
CONTROL CYCLO  13.92         
CGRP CYCLO  12.09         
SP CYCLO  15.34         
BOTH CYCLO  13.86         
RT NEG  NONE          
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Table 4.  Replicate 1: RT-PCR data after 4 days culture with and 
without neuropeptides showing cycle threshold C(T) value, which 
represents the PCR amplification cycle at which the fluorescent signal 
exceeds a background threshold level.  A Ct value was obtained for 
each osteoblast gene mRNA by subtracting the Ct value of cyclophilin 
mRNA from the Ct value of the mRNA for each sample.  To compare 
relative mRNA levels between treated and untreated cells at each time 
point, Ct was calculated as Control Ct – TreatedCt.  The ratio of 
Treated/Control mRNA levels was calculated as 2(∆∆Ct).  Ct value 
represents threshold cycle for PCR amplification cycle between cycle 
and reference.  ∆∆Ct represents the difference between ∆Ct(treated sample) 
and ∆Ct(untreated sample) for the same gene. 
 
 
  C(T)  ΔCt  ΔΔCt  2(ΔΔCt) 
CONTROL COX‐2  21.51 9.45      
CGRP COX‐2  22.27 10.29 ‐0.84  0.56
SP COX‐2  22.05 8.75 0.70  1.62
BOTH COX‐2  21.88 7.94 1.51  2.84
RT NEG  NONE          
              
CONTROL CYCLO  12.07         
CGRP CYCLO  11.98         
SP CYCLO  13.30         
BOTH CYCLO  13.94         
RT NEG  NONE          
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Table 5.  Replicate 2: RT-PCR data after 4 days culture with and 
without neuropeptides showing cycle threshold C(T) value, which 
represents the PCR amplification cycle at which the fluorescent signal 
exceeds a background threshold level.  A Ct value was obtained for 
each osteoblast gene mRNA by subtracting the Ct value of cyclophilin 
mRNA from the Ct value of the mRNA for each sample.  To compare 
relative mRNA levels between treated and untreated cells at each time 
point, Ct was calculated as Control Ct – TreatedCt.  The ratio of 
Treated/Control mRNA levels was calculated as 2(∆∆Ct).  Ct value 
represents threshold cycle for PCR amplification cycle between cycle 
and reference.  ∆∆Ct represents the difference between ∆Ct(treated sample) 
and ∆Ct(untreated sample) for the same gene. 
 
 
  C(T)  ΔCt  ΔΔCt  2(ΔΔCt) 
CONTROL COX‐2  23.10 9.14      
CGRP COX‐2  23.29 9.48 ‐0.34  0.79
SP COX‐2  22.19 8.07 1.07  2.10
BOTH COX‐2  21.27 7.28 1.86  3.63
RT NEG  NONE          
              
CONTROL CYCLO  13.96         
CGRP CYCLO  13.81         
SP CYCLO  14.12         
BOTH CYCLO  13.99         
RT NEG  NONE          
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Figure 27.  Real Time PCR data graph demonstrating the cycle number 
and fluorescence level for each sample.  Cycle threshold C(T) value 
represents the amplification cycle number at which the fluorescent 
signal exceeds the background threshold level (dotted line).  A Ct 
value was obtained for each osteoblast gene mRNA by subtracting the 
Ct value of cyclophilin mRNA from the Ct value of the mRNA for each 
sample.  To compare relative mRNA levels between treated and 
untreated cells at each time point, ∆∆Ct was calculated as Control Ct 
– Treated∆∆Ct.  The ratio of Treated/Control mRNA levels was 
calculated as 2(∆∆Ct).  Ct value represents threshold cycle for PCR 
amplification cycle between cycle and reference.  ∆∆Ct represents the 
difference between ∆Ct(treated sample) and ∆Ct(untreated sample) for the same 
gene. 
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Figure 28.  Real time PCR melting curve of a single sample 
representing product homogeneity as shown by a single peak at the 
given melting temperature. 
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Table 6.  Replicate 3: RT-PCR data after 4 days culture with and 
without neuropeptides showing cycle threshold C(T) value, which 
represents the PCR amplification cycle at which the fluorescent signal 
exceeds a background threshold level.  A Ct value was obtained for 
each osteoblast gene mRNA by subtracting the Ct value of cyclophilin 
mRNA from the Ct value of the mRNA for each sample.  To compare 
relative mRNA levels between treated and untreated cells at each time 
point, Ct was calculated as Control Ct – TreatedCt.  The ratio of 
Treated/Control mRNA levels was calculated as 2(∆∆Ct).  Ct value 
represents threshold cycle for PCR amplification cycle between cycle 
and reference.  ∆∆Ct represents the difference between ∆Ct(treated sample) 
and ∆Ct(untreated sample) for the same gene. 
 
             C(T)              ∆C(T)         ∆∆C(T)          2 (∆∆C(T)) 
mALP CONTROL 15.10 3.03   
mALP CGRP 16.72 5.00 1.97 3.91 
mALP SP 15.20 3.25 0.21 1.16 
mALP BOTH 15.45 3.99 0.96 1.95 
RT NEG None    
     
mBSP CONTROL 13.51 1.44   
mBSP CGRP 13.15 1.44 -0.00 0.99 
mBSP SP 13.98 2.02 0.57 1.48 
mBSP BOTH 14.09 2.63 1.18 2.27 
RT NEG None    
     
mCBFA1 CONTROL 16.8 4.73   
mCBFA1 CGRP 16.06 4.34 -0.38 0.76 
mCBFA1 SP 16.87 4.92 0.18 1.13 
mCBFA1 BOTH 16.14 4.68 -0.04 0.97 
RT NEG None    
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Table 6. Continued 
 
           C(T)         ∆C(T)         ∆∆C(T)      2 (∆∆C(T)) 
mCOL CONTROL 8.36 -3.70   
mCOL CGRP 8.71 -3.00 0.70 1.62 
mCOL SP 7.95 -3.99 0.77 2.08 
mCOL BOTH 7.60 -3.84 -0.14 0.90 
RT NEG None    
     
mOC CONTROL 15.28 3.21   
mOC CGRP 15.57 3.86 0.64 1.56 
mOC SP 15.87 3.92 0.70 1.63 
mOC BOTH 15.60 4.14 0.93 1.90 
RT NEG None    
     
mOSX CONTROL 18.06 5.99   
mOSX CGRP 17.94 6.22 0.22 1.17 
mOSX SP 18.06 6.10 0.10 1.07 
mOSX BOTH 18.04 6.58 0.10 1.07 
RT NEG None    
     
mCYCLO CONTROL 12.06    
mCYCLO CGRP 11.71    
mCYCLO SP 11.95    
mCYCLO BOTH 11.45    
RT NEG None    
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As shown above, COX-2 mRNA expression levels demonstrated 
measurable differences in osteoblastic cells treated with neuropeptides 
CGRP and SP.  Although the mechanisms are not known, the effect to 
increase COX-2 message levels may suggest a role for prostaglandins.  
Initial studies using COX-2 inhibitor, indomethacin, demonstrate a 
visible decrease in osteoblast mineralization when indomethacin is 
present in levels 1-10 M.  For these studies, MC3T3-E1 cells were 
plated in 6-well plates at 30,000-40,000 cells/ml, in a volume of 2.0 
ml/well.  When the cells were 80% confluent, the culture medium was 
supplemented with 50 g/ml ascorbic acid and 10 mM ß-glycerol-
phosphate to support mineralization in the presence of indomethacin 
with and without addition of neuropeptides; 3 replicate wells 
containing indomethacin and 3 replicate wells containing indomethacin 
with neuropeptides.  Media was replaced and fresh peptides were 
added every other day.  After 7–14 days, cells were rinsed 5 times 
with PBS and fixed for one hour at 4°C with 10% formalin in PBS.  
Alizarin red solution (40mM, pH 4.2) was applied to the fixed cells for 
10 minutes at room temperature. 
Initially, cells were not surviving in the presence of indomethacin 
at 10 M; therefore, concentrations were diluted to 1 M for the 
experiment.  Peptides were used in concentrations from prior 
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experiments (1.0g/mL SP + 1.0g/mL CGRP).  Equal amount of 
dilution buffer was added to indomethacin-only wells. 
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Figure 29.  Mineralization of MC3T3-E1 osteoblastic cells after 7 days 
of growth with (1) Control, (2) Neuropeptides, (3) COX-2 inhibitor, 
indomethacin, and (4) Indomethacin plus neuropeptides.  Osteoblasts 
treated with COX-2 inhibitor, indomethacin, appear with decreased 
mineralization.  Addition of neuropeptides, even in presence of 
indomethacin, appears to increase mineralization, as shown by alizarin 
red staining. 
 
Control Peptides 
+ Indomethacin 
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CHAPTER FOUR 
DISCUSSION 
 
The present study examined the effects of two neuropeptides, 
CGRP and SP, on osteoblast growth and mineralization.  Although the 
presence of these neuropeptides throughout bone has already been 
established (Hill and Elde 1991; Hukkanen, Konttinen et al. 1993), the 
potential role(s) of CGRP and SP as direct effectors of osteoblasts has 
not been assessed.  Previous studies have shown that CGRP can 
increase cAMP production in osteoblasts (Michelangeli, Fletcher et al. 
1989), and that osteoblasts possess receptors for both CGRP and SP 
(Michelangeli, Fletcher et al. 1989; Bjurholm 1991; Bjurholm, 
Kreicbergs et al. 1992).  The results of the present studies have 
confirmed and extended those findings by demonstrating direct, in 
vitro effects of these two neuropeptides on the differentiation and 
mineralization of murine osteoblasts. 
The effects of CGRP on alkaline phosphatase activity are 
consistent with previous studies (Michelangeli, Fletcher et al. 1989; 
Bjurholm 1991; Bjurholm, Kreicbergs et al. 1992).  The effects of SP 
on alkaline phosphatase activity have not been previously reported.  
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Our observations of the interactive effects of CGRP and SP on 
differentiation, as reflected by the increase in alkaline phosphatase 
specific activity are also novel.  Previous studies have not investigated 
the effects of these two peptides in combination; it is interesting to 
speculate that the effects of the combination of CGRP and SP may be 
physiologically relevant as these peptides frequently co-localize. 
Although previous studies have demonstrated effects of CGRP on 
bone marrow mononucleated cells, i.e., CGRP stimulated bone colony 
formation both in vitro and in vivo (Bernard and Shih 1990), the 
present study is the first to demonstrate the effects of SP on 
osteoblastic mineralization.  The current data demonstrate the 
neuropeptides, CGRP and SP, alone or in combination, can increase 
the rate and the extent of mineralization, at least, in our cell culture 
model.  These findings suggest that neuropeptides released from 
neurons in bone may be involved in the regulation of bone formation, 
by means of direct effects on osteoblast growth and mineralization. 
The mechanisms for these neuropeptides to affect osteoblasts 
are not clear; however the results of our RT-PCR studies have revealed 
significant effects of CGRP and SP on COX-2 mRNA expression.  This, 
in addition to the known role of neuropeptides in neurogenic 
inflammation, suggests a possible role of neuropeptides in bone 
metabolism during inflammatory processes.  With respect to the 
81 
osteogenic responses of osteoblast-line cells to CGRP and SP, the 
effect to increase COX-2 message levels may also suggest a 
mechanistic role for prostaglandin(s).  Further studies (e.g., using 
COX-2 inhibitors) will be required to assess this new hypothesis. 
Physiologically, the results of this study are consistent with the 
possible functional significance of these neuropeptides in bone.  
Physiologic levels of neuropeptides are difficult to measure as amounts 
vary widely at different times in various tissues.  Measurable values in 
body fluids range from 3 pg/ml-1 ng/ml of peptide (Itoh, Nagaya et al. 
2004); we have observed effects at concentrations in the range of 1 
ng/ml-10 ug/ml. 
Proposed physiologic mechanisms for these neuropeptides 
include regulation of blood flow, osteoclast inhibition, activation of 
second messenger systems, increased IGF-1 production, Ca2+ 
regulation, and immune and/or inflammatory response (Michelangeli, 
Fletcher et al. 1989; Kawase, Howard et al. 1995; Vignery and 
McCarthy 1996; Villa, Melzi et al. 2000; Fernandez, Chen et al. 2003; 
Kawase, Okuda et al. 2003; Lundy and Linden 2004).  Since both 
peptides are known to increase vasodilation, many different 
physiological effects would be possible through this pathway.  Nerves 
and blood vessels typically travel together throughout the body and 
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usually enter bone as a neurovascular bundle allowing nerves to 
regulate blood flow in and around bone. 
Clinically, patients with spinal cord injuries often develop 
abnormal bone formation known as heterotopic ossification.  The cause 
of this painful condition is unknown.  Since these patients obviously 
have altered nerves and neuropeptides, the relationship between bone 
cells and neuroptides may be involved. Alternatively, decreased 
norepinephrine release or action due to impaired sympathetic 
innervation at tissue trauma sites may contribute to heterotopic 
ossification.  β2-adrenergic receptor knockout mice have increased 
bone formation, and beta adrenergic antagonists increase bone 
formation (Elefteriou 2008).  
Interestingly, COX-2 inhibitors have been shown to be effective 
in preventing heterotopic ossification (Murat, Hocaoglu et al. 2005; 
Grohs, Schmidt et al. 2007; Tsailas, Babis et al. 2009; Xue, Zheng et 
al. 2011).  This medical “enigma” may be explained using the 
knowledge that neuropeptides are involved in both regulation of bone 
cells and regulation of COX-2 production.  Therefore, this bone 
disorder occurring after neural injuries could be explored further 
regarding relationship between bone cells, neuropeptides, and COX-2. 
Although further studies are, clearly, required to assess the 
possible role of neuropeptide secretion as a local, site-specific 
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determinant of bone formation (and the possible mechanistic role of 
COX-2 as a mediator of that process), several findings from previous 
studies are consistent with the premise.  Increased sensory and 
sympathetic innervation of fracture calluses have been reported in 
previous animal studies (Hukkanen, Konttinen et al. 1993; Grills and 
Schuijers 1998).  Clinical treatments, such as nerve blocks and nerve 
resections, may affect bone metabolism partially through neuropeptide 
pathways.  Other treatments, including non-steroidal anti-
inflammatory medications, inhibit COX-2; since COX-2 is potentially 
involved with fracture healing, these treatments may affect the healing 
process partially through the neuropeptide pathway as well. 
Additional studies may include an in vivo fracture-healing model 
to determine the effect of neuropeptides which we have found to be 
effective in cell cultures on fracture callus formation, healing rate, and 
gene expression.  In vitro studies might include examining the effect 
of CGRP and SP on apoptosis.  Receptor studies might include 
measuring the effect of NK-1 and/or CGRP receptor antagonists on 
differentiation and mineralization.  Although we examined a number of 
osteoblast-related mRNAs, there are many other genes, proteins, and 
transcription factors that could be measured, including osteopontin, 
osteonectin, fibronectin, c-myc, c-fos, TGF, FGF, IGF, etc.  Since COX-
2 mRNA was affected by treatment with neuropeptides, it would be 
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interesting to examine interleukins, prostaglandins, arachadonic acid, 
and other inflammatory substances.  The COX-2 culture experiments 
could be expanded by testing effects of various COX-2 inhibitors with 
and without neuropeptides.  The clinical relevance could be examined 
through retrospective or prospective studies; clinical studies could 
examine the effects of COX-2 inhibitors on patients who have suffered 
fractures. 
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